| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 11 | 2025 | 38 | 2.980 |
Why?
|
| Immune Tolerance | 6 | 2025 | 50 | 2.590 |
Why?
|
| Air Pollution | 4 | 2022 | 18 | 2.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2025 | 409 | 1.820 |
Why?
|
| Intellectual Disability | 5 | 2024 | 16 | 1.660 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2018 | 18 | 1.570 |
Why?
|
| Cross Infection | 6 | 2025 | 37 | 1.480 |
Why?
|
| Sepsis | 5 | 2025 | 84 | 1.330 |
Why?
|
| Interleukin-10 | 5 | 2018 | 72 | 1.290 |
Why?
|
| Middle Aged | 38 | 2025 | 7138 | 1.180 |
Why?
|
| Ireland | 11 | 2025 | 16 | 1.180 |
Why?
|
| Psychotropic Drugs | 2 | 2018 | 8 | 1.130 |
Why?
|
| Male | 51 | 2025 | 13491 | 1.130 |
Why?
|
| Aged | 33 | 2025 | 5400 | 1.110 |
Why?
|
| Air Pollutants | 3 | 2022 | 18 | 1.100 |
Why?
|
| Humans | 78 | 2025 | 28097 | 1.100 |
Why?
|
| Interferon-gamma | 6 | 2018 | 107 | 1.050 |
Why?
|
| Wounds and Injuries | 4 | 2018 | 183 | 1.040 |
Why?
|
| Female | 48 | 2025 | 15156 | 1.030 |
Why?
|
| Gene Expression Regulation | 8 | 2015 | 632 | 1.030 |
Why?
|
| Antibodies, Monoclonal | 7 | 2025 | 330 | 1.030 |
Why?
|
| Postoperative Complications | 7 | 2018 | 611 | 0.980 |
Why?
|
| Perioperative Period | 2 | 2015 | 7 | 0.950 |
Why?
|
| Cytokines | 9 | 2020 | 447 | 0.940 |
Why?
|
| Adult | 31 | 2025 | 7740 | 0.900 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 6 | 2020 | 44 | 0.890 |
Why?
|
| Monocytes | 4 | 2020 | 135 | 0.890 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2021 | 37 | 0.880 |
Why?
|
| Asthma | 2 | 2022 | 60 | 0.870 |
Why?
|
| Aged, 80 and over | 18 | 2025 | 2021 | 0.870 |
Why?
|
| Dexamethasone | 7 | 2025 | 63 | 0.840 |
Why?
|
| Hospitalization | 3 | 2022 | 198 | 0.820 |
Why?
|
| RNA, Messenger | 10 | 2018 | 659 | 0.800 |
Why?
|
| Nitrogen Dioxide | 2 | 2022 | 6 | 0.790 |
Why?
|
| Elective Surgical Procedures | 4 | 2018 | 70 | 0.770 |
Why?
|
| Transcription, Genetic | 3 | 2014 | 403 | 0.700 |
Why?
|
| Mesenteric Ischemia | 1 | 2020 | 1 | 0.690 |
Why?
|
| Embolism, Air | 1 | 2020 | 2 | 0.690 |
Why?
|
| Respiratory Tract Diseases | 1 | 2020 | 3 | 0.690 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2020 | 5 | 0.690 |
Why?
|
| Gene Expression | 4 | 2015 | 417 | 0.670 |
Why?
|
| Betacoronavirus | 1 | 2020 | 39 | 0.660 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 49 | 0.640 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 53 | 0.640 |
Why?
|
| MicroRNAs | 3 | 2021 | 301 | 0.620 |
Why?
|
| Interleukin-6 | 4 | 2016 | 193 | 0.620 |
Why?
|
| Multiple Trauma | 2 | 2015 | 23 | 0.600 |
Why?
|
| Anticonvulsants | 1 | 2018 | 20 | 0.580 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 46 | 0.570 |
Why?
|
| Epilepsy | 1 | 2018 | 35 | 0.560 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2016 | 21 | 0.560 |
Why?
|
| Polypharmacy | 1 | 2017 | 11 | 0.560 |
Why?
|
| Aging | 4 | 2024 | 968 | 0.550 |
Why?
|
| Inflammation | 7 | 2020 | 636 | 0.540 |
Why?
|
| Bacteriological Techniques | 1 | 2016 | 18 | 0.530 |
Why?
|
| Blood | 1 | 2016 | 34 | 0.530 |
Why?
|
| Retrospective Studies | 10 | 2025 | 2546 | 0.530 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 366 | 0.510 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 50 | 0.500 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 28 | 0.490 |
Why?
|
| Immune System Phenomena | 1 | 2015 | 1 | 0.490 |
Why?
|
| Treatment Outcome | 9 | 2025 | 2379 | 0.480 |
Why?
|
| Interleukin-27 | 1 | 2015 | 1 | 0.480 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 306 | 0.480 |
Why?
|
| Blood Preservation | 1 | 2015 | 9 | 0.480 |
Why?
|
| Erythrocyte Transfusion | 1 | 2015 | 15 | 0.470 |
Why?
|
| Transfusion Reaction | 1 | 2014 | 10 | 0.460 |
Why?
|
| Blood Transfusion | 2 | 2015 | 77 | 0.460 |
Why?
|
| Young Adult | 10 | 2020 | 2733 | 0.460 |
Why?
|
| Transcription Factors | 2 | 2015 | 520 | 0.450 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2010 | 247 | 0.440 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 147 | 0.440 |
Why?
|
| Bacteria | 1 | 2016 | 281 | 0.440 |
Why?
|
| Critical Care | 5 | 2018 | 49 | 0.430 |
Why?
|
| Cyclophosphamide | 4 | 2022 | 41 | 0.430 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2016 | 20 | 0.410 |
Why?
|
| Bortezomib | 3 | 2022 | 22 | 0.400 |
Why?
|
| Comorbidity | 6 | 2024 | 258 | 0.390 |
Why?
|
| Bacteremia | 5 | 2015 | 80 | 0.390 |
Why?
|
| Risk Factors | 7 | 2025 | 2081 | 0.380 |
Why?
|
| Prospective Studies | 8 | 2017 | 1248 | 0.380 |
Why?
|
| Interleukin-17 | 2 | 2010 | 52 | 0.370 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 42 | 0.360 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 269 | 0.350 |
Why?
|
| Arabinonucleosides | 1 | 2010 | 1 | 0.350 |
Why?
|
| Adenine Nucleotides | 1 | 2010 | 2 | 0.350 |
Why?
|
| Injury Severity Score | 3 | 2015 | 121 | 0.350 |
Why?
|
| Proteasome Inhibitors | 3 | 2019 | 26 | 0.340 |
Why?
|
| Prognosis | 5 | 2025 | 803 | 0.340 |
Why?
|
| Pyrimidines | 3 | 2019 | 125 | 0.340 |
Why?
|
| Cohort Studies | 6 | 2024 | 887 | 0.340 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 82 | 0.330 |
Why?
|
| Killer Cells, Natural | 2 | 2020 | 63 | 0.330 |
Why?
|
| Genetic Variation | 2 | 2008 | 242 | 0.330 |
Why?
|
| Tumor Microenvironment | 4 | 2025 | 178 | 0.330 |
Why?
|
| Amidohydrolases | 2 | 2006 | 12 | 0.320 |
Why?
|
| Interleukin-23 | 2 | 2010 | 8 | 0.310 |
Why?
|
| Case-Control Studies | 5 | 2016 | 722 | 0.310 |
Why?
|
| Survival Analysis | 6 | 2018 | 288 | 0.310 |
Why?
|
| Pneumonia | 4 | 2019 | 89 | 0.310 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 165 | 0.300 |
Why?
|
| Prevalence | 4 | 2019 | 497 | 0.300 |
Why?
|
| Anxiety | 2 | 2020 | 149 | 0.290 |
Why?
|
| Interleukin-18 | 1 | 2008 | 17 | 0.290 |
Why?
|
| Respiration, Artificial | 2 | 2020 | 41 | 0.290 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 156 | 0.280 |
Why?
|
| Acute Kidney Injury | 2 | 2018 | 74 | 0.280 |
Why?
|
| Abscess | 1 | 2007 | 24 | 0.280 |
Why?
|
| Abdomen | 2 | 2018 | 41 | 0.280 |
Why?
|
| Depression | 2 | 2020 | 216 | 0.280 |
Why?
|
| Pyrazoles | 2 | 2019 | 66 | 0.270 |
Why?
|
| Aortic Valve | 1 | 2007 | 92 | 0.270 |
Why?
|
| Neutropenia | 4 | 2019 | 41 | 0.270 |
Why?
|
| Time Factors | 5 | 2020 | 1592 | 0.270 |
Why?
|
| Acute Coronary Syndrome | 1 | 2007 | 64 | 0.260 |
Why?
|
| Shock | 1 | 2006 | 17 | 0.260 |
Why?
|
| Arginine | 2 | 2006 | 42 | 0.260 |
Why?
|
| Flow Cytometry | 4 | 2020 | 289 | 0.260 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2006 | 2 | 0.260 |
Why?
|
| Trauma Centers | 3 | 2017 | 118 | 0.260 |
Why?
|
| Community-Acquired Infections | 2 | 2025 | 31 | 0.260 |
Why?
|
| Age Factors | 2 | 2020 | 734 | 0.250 |
Why?
|
| Motor Skills | 2 | 2017 | 34 | 0.250 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2016 | 71 | 0.250 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 961 | 0.250 |
Why?
|
| Adolescent | 5 | 2020 | 3122 | 0.250 |
Why?
|
| Shock, Septic | 1 | 2006 | 38 | 0.250 |
Why?
|
| Coronary Artery Bypass | 1 | 2006 | 68 | 0.250 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2025 | 5 | 0.240 |
Why?
|
| Child Development | 2 | 2017 | 78 | 0.240 |
Why?
|
| Stromal Cells | 1 | 2025 | 61 | 0.240 |
Why?
|
| Lung | 3 | 2020 | 379 | 0.230 |
Why?
|
| Particulate Matter | 2 | 2022 | 17 | 0.230 |
Why?
|
| Leukemia | 2 | 2015 | 30 | 0.230 |
Why?
|
| Unfolded Protein Response | 2 | 2015 | 25 | 0.230 |
Why?
|
| Proteomics | 1 | 2006 | 181 | 0.230 |
Why?
|
| Hospitals | 2 | 2022 | 77 | 0.230 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 17 | 0.220 |
Why?
|
| Consensus | 1 | 2024 | 75 | 0.220 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 371 | 0.220 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2020 | 28 | 0.220 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2010 | 82 | 0.210 |
Why?
|
| Macrophages | 3 | 2021 | 295 | 0.200 |
Why?
|
| Apoptosis | 4 | 2020 | 775 | 0.200 |
Why?
|
| Europe | 3 | 2016 | 98 | 0.190 |
Why?
|
| Biomarkers | 5 | 2019 | 765 | 0.190 |
Why?
|
| Environmental Pollutants | 1 | 2022 | 35 | 0.190 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2021 | 2 | 0.190 |
Why?
|
| Signal Transduction | 8 | 2020 | 1435 | 0.190 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 22 | 0.190 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 41 | 0.180 |
Why?
|
| Child, Preschool | 3 | 2020 | 1146 | 0.180 |
Why?
|
| Mutation | 4 | 2020 | 847 | 0.180 |
Why?
|
| Mountaineering | 2 | 2012 | 6 | 0.180 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 263 | 0.170 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2020 | 14 | 0.170 |
Why?
|
| Remission, Spontaneous | 1 | 2020 | 8 | 0.170 |
Why?
|
| Portal Vein | 1 | 2020 | 8 | 0.170 |
Why?
|
| Incidence | 2 | 2019 | 562 | 0.170 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 13 | 0.170 |
Why?
|
| Disease Susceptibility | 3 | 2019 | 74 | 0.170 |
Why?
|
| Staining and Labeling | 1 | 2020 | 69 | 0.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 28 | 0.170 |
Why?
|
| Hospital Mortality | 2 | 2025 | 147 | 0.170 |
Why?
|
| Early Diagnosis | 2 | 2016 | 32 | 0.160 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2019 | 1 | 0.160 |
Why?
|
| ADAM17 Protein | 1 | 2019 | 13 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2019 | 21 | 0.160 |
Why?
|
| Hypoxia | 1 | 2020 | 89 | 0.160 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 60 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 29 | 0.160 |
Why?
|
| Pancreatitis | 1 | 2019 | 36 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 44 | 0.160 |
Why?
|
| Intestines | 1 | 2020 | 118 | 0.160 |
Why?
|
| Critical Illness | 2 | 2016 | 66 | 0.160 |
Why?
|
| Hemorrhage | 2 | 2019 | 265 | 0.160 |
Why?
|
| Risk Assessment | 3 | 2016 | 612 | 0.150 |
Why?
|
| Problem Behavior | 1 | 2019 | 14 | 0.150 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2018 | 19 | 0.150 |
Why?
|
| Survival Rate | 3 | 2025 | 430 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 328 | 0.150 |
Why?
|
| HLA-DR Antigens | 1 | 2018 | 29 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 186 | 0.150 |
Why?
|
| Cells, Cultured | 3 | 2018 | 985 | 0.150 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 54 | 0.150 |
Why?
|
| Alleles | 3 | 2008 | 350 | 0.140 |
Why?
|
| Health Status | 1 | 2019 | 148 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2017 | 15 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2019 | 110 | 0.140 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 24 | 0.140 |
Why?
|
| Chromosome Aberrations | 1 | 2017 | 37 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 474 | 0.140 |
Why?
|
| Infant | 2 | 2020 | 1004 | 0.140 |
Why?
|
| Multiple Organ Failure | 1 | 2017 | 31 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 208 | 0.140 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2017 | 36 | 0.140 |
Why?
|
| Exons | 1 | 2017 | 42 | 0.140 |
Why?
|
| Calreticulin | 1 | 2017 | 5 | 0.140 |
Why?
|
| Myeloproliferative Disorders | 1 | 2017 | 12 | 0.140 |
Why?
|
| Play and Playthings | 1 | 2017 | 9 | 0.140 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2007 | 64 | 0.130 |
Why?
|
| Waste Management | 1 | 2016 | 1 | 0.130 |
Why?
|
| Fats | 1 | 2016 | 6 | 0.130 |
Why?
|
| Industrial Waste | 1 | 2016 | 7 | 0.130 |
Why?
|
| Infant, Newborn | 1 | 2020 | 885 | 0.130 |
Why?
|
| Waste Disposal, Fluid | 1 | 2016 | 12 | 0.130 |
Why?
|
| Sewage | 1 | 2016 | 21 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 679 | 0.130 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 38 | 0.130 |
Why?
|
| Stress, Psychological | 1 | 2019 | 221 | 0.130 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2016 | 5 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 1013 | 0.130 |
Why?
|
| Neoplasms | 1 | 2025 | 809 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 302 | 0.130 |
Why?
|
| Chlorambucil | 1 | 2015 | 2 | 0.130 |
Why?
|
| Risk | 1 | 2016 | 137 | 0.130 |
Why?
|
| Blood-Borne Pathogens | 1 | 2015 | 2 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2017 | 84 | 0.120 |
Why?
|
| Motor Activity | 1 | 2017 | 148 | 0.120 |
Why?
|
| Interleukin-12 | 1 | 2015 | 19 | 0.120 |
Why?
|
| Pneumonia, Bacterial | 1 | 2015 | 18 | 0.120 |
Why?
|
| Anesthetics | 1 | 2015 | 9 | 0.120 |
Why?
|
| United Kingdom | 1 | 2015 | 76 | 0.120 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2015 | 9 | 0.120 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 72 | 0.120 |
Why?
|
| Fungemia | 1 | 2015 | 5 | 0.120 |
Why?
|
| Analgesics | 1 | 2015 | 38 | 0.120 |
Why?
|
| GATA3 Transcription Factor | 1 | 2015 | 2 | 0.120 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Causality | 1 | 2015 | 13 | 0.120 |
Why?
|
| Contraindications | 1 | 2015 | 13 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 35 | 0.120 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2015 | 34 | 0.120 |
Why?
|
| Leukocyte Count | 1 | 2014 | 25 | 0.120 |
Why?
|
| Respiration | 2 | 2012 | 45 | 0.120 |
Why?
|
| Child | 2 | 2020 | 2242 | 0.110 |
Why?
|
| Disease Progression | 3 | 2019 | 473 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2007 | 547 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 120 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 474 | 0.110 |
Why?
|
| Membrane Proteins | 2 | 2007 | 484 | 0.110 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2013 | 8 | 0.110 |
Why?
|
| Antibody-Producing Cells | 1 | 2013 | 15 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 42 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2013 | 49 | 0.100 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2013 | 39 | 0.100 |
Why?
|
| Phenotype | 1 | 2015 | 681 | 0.100 |
Why?
|
| Cell Separation | 2 | 2006 | 55 | 0.090 |
Why?
|
| Endoplasmic Reticulum | 2 | 2013 | 80 | 0.090 |
Why?
|
| Patient Preference | 1 | 2011 | 32 | 0.090 |
Why?
|
| Chemokine CCL2 | 2 | 2007 | 47 | 0.090 |
Why?
|
| Haplotypes | 2 | 2008 | 283 | 0.090 |
Why?
|
| Ubiquitins | 1 | 2010 | 7 | 0.080 |
Why?
|
| Cyclopentanes | 1 | 2010 | 13 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 1319 | 0.080 |
Why?
|
| Intensive Care Units | 3 | 2018 | 50 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2011 | 115 | 0.080 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2010 | 60 | 0.080 |
Why?
|
| Asphyxia | 1 | 2009 | 3 | 0.080 |
Why?
|
| Ventilation | 1 | 2009 | 6 | 0.080 |
Why?
|
| Survival | 1 | 2008 | 3 | 0.080 |
Why?
|
| Cytogenetics | 1 | 2008 | 5 | 0.080 |
Why?
|
| Disasters | 1 | 2009 | 16 | 0.080 |
Why?
|
| Immunophenotyping | 2 | 2019 | 60 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2017 | 521 | 0.070 |
Why?
|
| Cause of Death | 1 | 2008 | 73 | 0.070 |
Why?
|
| Equipment Design | 1 | 2009 | 217 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 414 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2008 | 185 | 0.070 |
Why?
|
| Hemochromatosis | 1 | 2007 | 3 | 0.070 |
Why?
|
| Adenine | 2 | 2019 | 17 | 0.070 |
Why?
|
| Exercise | 1 | 2012 | 479 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2007 | 67 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2021 | 490 | 0.070 |
Why?
|
| Diarrhea | 2 | 2019 | 55 | 0.070 |
Why?
|
| Protein Folding | 1 | 2007 | 47 | 0.070 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2007 | 8 | 0.070 |
Why?
|
| Leukocytes | 2 | 2006 | 71 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 20 | 0.070 |
Why?
|
| Animals | 6 | 2025 | 10423 | 0.070 |
Why?
|
| Fatigue | 2 | 2019 | 64 | 0.070 |
Why?
|
| Piperidines | 2 | 2019 | 48 | 0.070 |
Why?
|
| Blood Coagulation Disorders | 1 | 2007 | 26 | 0.070 |
Why?
|
| Lymphotoxin-alpha | 1 | 2006 | 1 | 0.070 |
Why?
|
| Norepinephrine | 1 | 2006 | 32 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 28 | 0.070 |
Why?
|
| Epinephrine | 1 | 2006 | 37 | 0.070 |
Why?
|
| Vasoconstrictor Agents | 1 | 2006 | 34 | 0.070 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2006 | 40 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 385 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2006 | 68 | 0.060 |
Why?
|
| Cell Survival | 2 | 2019 | 409 | 0.060 |
Why?
|
| Blood Platelets | 2 | 2006 | 206 | 0.060 |
Why?
|
| Sialic Acids | 1 | 2025 | 2 | 0.060 |
Why?
|
| Hospitals, Public | 1 | 2025 | 3 | 0.060 |
Why?
|
| Rituximab | 2 | 2017 | 63 | 0.060 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2025 | 10 | 0.060 |
Why?
|
| RNA | 1 | 2006 | 110 | 0.060 |
Why?
|
| Polysaccharides | 1 | 2025 | 62 | 0.060 |
Why?
|
| Cholinergic Antagonists | 1 | 2024 | 4 | 0.060 |
Why?
|
| Down Syndrome | 1 | 2024 | 19 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 173 | 0.060 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 29 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 77 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 453 | 0.050 |
Why?
|
| Vehicle Emissions | 1 | 2022 | 6 | 0.050 |
Why?
|
| Mice | 4 | 2021 | 4654 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 220 | 0.050 |
Why?
|
| Preleukemia | 1 | 2021 | 1 | 0.050 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2021 | 1 | 0.050 |
Why?
|
| Environmental Monitoring | 1 | 2022 | 66 | 0.050 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2021 | 10 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2021 | 23 | 0.050 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2021 | 10 | 0.040 |
Why?
|
| Fanconi Anemia | 1 | 2000 | 3 | 0.040 |
Why?
|
| Caspases | 1 | 2000 | 43 | 0.040 |
Why?
|
| CD2 Antigens | 1 | 2020 | 4 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 67 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2000 | 86 | 0.040 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 52 | 0.040 |
Why?
|
| Receptor, Notch1 | 1 | 2020 | 27 | 0.040 |
Why?
|
| Thymidine | 1 | 2020 | 7 | 0.040 |
Why?
|
| Cellular Microenvironment | 1 | 2020 | 6 | 0.040 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2020 | 4 | 0.040 |
Why?
|
| Tumor Escape | 1 | 2020 | 11 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2000 | 59 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2021 | 80 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2020 | 73 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2020 | 92 | 0.040 |
Why?
|
| Acute Disease | 2 | 2017 | 155 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2020 | 140 | 0.040 |
Why?
|
| Inflammation Mediators | 2 | 2014 | 165 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 97 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 134 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2019 | 12 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 95 | 0.040 |
Why?
|
| Drug Tolerance | 1 | 2019 | 37 | 0.040 |
Why?
|
| Safety | 1 | 2019 | 32 | 0.040 |
Why?
|
| Receptors, IgG | 1 | 2019 | 47 | 0.040 |
Why?
|
| Anemia | 1 | 2019 | 43 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2020 | 578 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 187 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 247 | 0.040 |
Why?
|
| Heart Rate | 2 | 2012 | 379 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2018 | 1 | 0.040 |
Why?
|
| Integrin alpha4 | 1 | 2018 | 3 | 0.040 |
Why?
|
| Quinazolinones | 1 | 2018 | 5 | 0.040 |
Why?
|
| Purines | 1 | 2018 | 16 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 157 | 0.040 |
Why?
|
| Proteins | 1 | 2000 | 252 | 0.040 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2018 | 35 | 0.040 |
Why?
|
| Cell Line | 1 | 2020 | 696 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 29 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 104 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 8 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2018 | 100 | 0.040 |
Why?
|
| Bone Marrow | 2 | 2013 | 76 | 0.040 |
Why?
|
| Vidarabine | 1 | 2017 | 3 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 769 | 0.040 |
Why?
|
| Hemochromatosis Protein | 2 | 2007 | 2 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2018 | 315 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 31 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2018 | 97 | 0.040 |
Why?
|
| London | 1 | 2017 | 10 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 75 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2017 | 17 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 94 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2017 | 52 | 0.030 |
Why?
|
| DNA Probes | 1 | 2017 | 13 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 34 | 0.030 |
Why?
|
| Antifibrinolytic Agents | 1 | 2017 | 25 | 0.030 |
Why?
|
| Food Industry | 1 | 2016 | 2 | 0.030 |
Why?
|
| Logistic Models | 1 | 2018 | 407 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 133 | 0.030 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 81 | 0.030 |
Why?
|
| Cell Movement | 1 | 2018 | 373 | 0.030 |
Why?
|
| Hypertension | 1 | 2019 | 308 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 145 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2017 | 97 | 0.030 |
Why?
|
| Schools | 1 | 2017 | 81 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 478 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 243 | 0.030 |
Why?
|
| Body Fluids | 1 | 2015 | 18 | 0.030 |
Why?
|
| Transcriptome | 1 | 2017 | 214 | 0.030 |
Why?
|
| Gram-Positive Bacteria | 1 | 2015 | 33 | 0.030 |
Why?
|
| England | 1 | 2015 | 39 | 0.030 |
Why?
|
| Specimen Handling | 1 | 2015 | 33 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 237 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 246 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2018 | 806 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 2015 | 62 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 402 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2016 | 226 | 0.030 |
Why?
|
| Transfection | 2 | 2007 | 318 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 128 | 0.030 |
Why?
|
| Recurrence | 1 | 2013 | 322 | 0.020 |
Why?
|
| Altitude | 1 | 2012 | 14 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 135 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 134 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 741 | 0.020 |
Why?
|
| Oxygen | 1 | 2012 | 233 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2010 | 5 | 0.020 |
Why?
|
| NEDD8 Protein | 1 | 2010 | 6 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 35 | 0.020 |
Why?
|
| Cullin Proteins | 1 | 2010 | 11 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 114 | 0.020 |
Why?
|
| Demography | 1 | 2010 | 93 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 75 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2010 | 80 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 257 | 0.020 |
Why?
|
| Skiing | 1 | 2009 | 1 | 0.020 |
Why?
|
| Snow | 1 | 2009 | 2 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2010 | 191 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 269 | 0.020 |
Why?
|
| Communication | 1 | 2011 | 178 | 0.020 |
Why?
|
| DNA Damage | 1 | 2010 | 151 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 514 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 285 | 0.020 |
Why?
|
| Transferrin | 1 | 2007 | 10 | 0.020 |
Why?
|
| Homozygote | 1 | 2007 | 36 | 0.020 |
Why?
|
| Taurochenodeoxycholic Acid | 1 | 2007 | 1 | 0.020 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2007 | 4 | 0.020 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2007 | 4 | 0.020 |
Why?
|
| Transcription Factor CHOP | 1 | 2007 | 7 | 0.020 |
Why?
|
| Ferritins | 1 | 2007 | 27 | 0.020 |
Why?
|
| Heterozygote | 1 | 2007 | 65 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 430 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2007 | 44 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2007 | 93 | 0.020 |
Why?
|
| Protein Transport | 1 | 2007 | 158 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 971 | 0.020 |
Why?
|
| Casein Kinase II | 1 | 2006 | 17 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 452 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2006 | 50 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 58 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2006 | 67 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 28 | 0.020 |
Why?
|
| Iron | 1 | 2007 | 116 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2006 | 81 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2006 | 92 | 0.020 |
Why?
|
| Vasodilation | 1 | 2006 | 114 | 0.020 |
Why?
|
| Genotype | 1 | 2006 | 456 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 163 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 466 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 666 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 1 | 2000 | 1 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2000 | 8 | 0.010 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2000 | 4 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2000 | 16 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2000 | 10 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2000 | 13 | 0.010 |
Why?
|
| fas Receptor | 1 | 2000 | 19 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 42 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2000 | 58 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 2000 | 31 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2000 | 151 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 267 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 233 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2000 | 413 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2000 | 848 | 0.010 |
Why?
|
| Leukemia, Lymphoid | 1 | 1975 | 3 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 1975 | 6 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2000 | 1576 | 0.010 |
Why?
|